

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[x] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as First Class mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: January 16, 2004

Name of Person Certifying: Melissa Sanchez

Printed Name:

Melissa Sanchez

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Crystal Cunanan et al.

Group Art Unit: 1746

Serial No.: 10/620,712

Examiner: Unassigned

Filing Date: July 16, 2003

Title: ENHANCED PHOSPHOLIPID REDUCTION AND CALCIFICATION MITIGATION OF BIOLOGICAL MATERIALS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- [] With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- [] With a Request For Continued Examination (RCE) under 37 C.F.R. § 1.114.
- [] Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. §1.491.
- [X] Before the mailing date of a first Office Action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement,

- ☐ the Commissioner is hereby authorized to charge Deposit Account No. 50-1225, Docket No. ECV-5665, for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
- ☒ the statement specified in 37 C.F.R. § 1.97(e) is provided below in accordance with 37 C.F.R. § 1.97(c)(1).

This Information Disclosure Statement is filed:

- ☐ After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first.
- ☐ the Commissioner is hereby authorized to charge Deposit Account No. 50-1225, Docket No. _____, for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
- ☐ the statement specified in 37 C.F.R. § 1.97(e) is provided below in accordance with 37 C.F.R. § 1.97(c)(1).

This Information Disclosure Statement is filed:

- ☐ After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

The undersigned certifies that:

- ☒ Each item of information contained in the Information Disclosure Statement was first cited in a communication mailed from any foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry,

was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

II. Copies of the Cited Items:

- ☐ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
- ☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed:_____.
- ☐ Copies of those items which are marked with an asterisk(*) in the attached form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent office in prior application No._____, filed on _____, and relied upon in this application for an earlier filing date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).
- ☒ Copies of those items which are marked with an asterisk(**) in the attached Form PTO-1449 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

- ☐ A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
- ☒ A concise explanation of relevance of the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application which refers to the relevant portions of the references (copy attached).

IV. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The commissioner is hereby authorized to charge Deposit Account No. 50-1225, Docket ECV-5665 any additional fees required in connection with the filing of this Information Disclosure Statement.


Date: January 16, 2004

Respectfully submitted,

By: 

Rajiv Yadav
Registration No. 43,999
Edwards Lifesciences LLC
Law Department
One Edwards Way
Irvine, California 92614
Telephone: (949) 250-6801
Facsimile: (949) 250-6850

Customer No. 30452

<div style="text-align: center;">  </div>	Docket Number (Optional) ECV-5665	Application Number 10/620,712
	Applicant(s) Cunanan et al.	
	Filing Date July 16, 2003	Group Art Unit 1746

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 02/43778	6/06/02	PCT				
		WO 84/01879	5/24/84	PCT				
		WO 98/56432	12/17/98	PCT				
		WO 90/09102	08/23/90	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		International Search Report for PCT/US 03/22121
		XP-002243892, Heat Treatment Mitigates Calcification of Valvular Bioprostheses, Carpentier et al., Annals of Thoracic Surgery, Vol. 66, No. 6, Pages S264-S266, December 1998

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.